Edgewood Oncology Funding & Investors

Edgewood Oncology is a clinical-stage biotechnology business established to fulfill the potential of BTX-A51 for patients with solid tumors that are genetically specified and hematologic malignancies. Our goal is to create a novel treatment that will prolong and enhance the lives of those with the greatest unmet medical needs.